Transistor (https://transistor.fm) https://feeds.transistor.fm/iga-nephropathy-current-treatment-landscape-disease-burden-and-2-year-protect-trial-data-supporting-sparsentan-as-an-emerging-treatment-option Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial © 2025 Travere Therapeutics ad9874df-d2d2-5040-aea5-31d1b3d4d6db no en Tue, 06 Aug 2024 14:04:18 -0700 Tue, 02 Dec 2025 20:05:18 -0800 https://img.transistor.fm/07S1YcrMBkEm0DAyGR21GTWl5Wc8jHsoJ7KaVY5VTYo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zMWVi/ZGM2ZGIzZTg2YjE1/ZGE1MjllMTBhMWM1/NjlkZS5wbmc.jpg episodic Travere Therapeutics Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial . IgAN, IgA Nephropathy, kidney disease, sparsentan Travere Therapeutics No No 1 1 IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option full 44ed7e70-8f1d-48fc-a718-e3cf37ebe9cd https://share.transistor.fm/s/780b3217 In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.

]]> In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.

]]> Tue, 07 May 2024 13:45:40 -0700 Travere Therapeutics Travere Therapeutics 971 In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.

]]> IgAN, IgA Nephropathy, kidney disease, sparsentan No